ATE344835T1 - Antisense-oligonukleotide gegen thymidylatsynthase - Google Patents

Antisense-oligonukleotide gegen thymidylatsynthase

Info

Publication number: ATE344835T1
Authority: AT; Austria
Prior art keywords: mrna; sequences; antisense oligonucleotides; oligonucleotides targeted; thymidylate synthase
Prior art date: 1997-09-23

Application number

AT98942944T

Other languages

English (en)

Inventor

Donald James Koropatnick

Mark David Vincent

Nicholas Mark Dean

Original Assignee

Sarissa Inc

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-23

Filing date

1998-09-17

Publication date

2006-11-15

1997-09-23 Priority claimed from GBGB9720107.3A external-priority patent/GB9720107D0/en

1997-10-17 Priority claimed from GBGB9722012.3A external-priority patent/GB9722012D0/en

1998-06-06 Priority claimed from GBGB9812140.3A external-priority patent/GB9812140D0/en

1998-09-17 Application filed by Sarissa Inc, Isis Pharmaceuticals Inc filed Critical Sarissa Inc

2006-11-15 Application granted granted Critical

2006-11-15 Publication of ATE344835T1 publication Critical patent/ATE344835T1/de

Links

108010022394 Threonine synthase Proteins 0.000 title abstract 5
102000005497 Thymidylate Synthase Human genes 0.000 title abstract 5
239000000074 antisense oligonucleotide Substances 0.000 title abstract 4
238000012230 antisense oligonucleotides Methods 0.000 title abstract 4
108020000948 Antisense Oligonucleotides Proteins 0.000 title abstract 3
108020004999 messenger RNA Proteins 0.000 abstract 3
108091034117 Oligonucleotide Proteins 0.000 abstract 2
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 abstract 2
239000002246 antineoplastic agent Substances 0.000 abstract 2
239000013066 combination product Substances 0.000 abstract 2
229940127555 combination product Drugs 0.000 abstract 2
229960004432 raltitrexed Drugs 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
101150112897 TS gene Proteins 0.000 abstract 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
230000010261 cell growth Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
229960002989 glutamic acid Drugs 0.000 abstract 1
230000001988 toxicity Effects 0.000 abstract 1
231100000419 toxicity Toxicity 0.000 abstract 1
238000013518 transcription Methods 0.000 abstract 1
230000035897 transcription Effects 0.000 abstract 1
210000004881 tumor cell Anatomy 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Physics & Mathematics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)

AT98942944T 1997-09-23 1998-09-17 Antisense-oligonukleotide gegen thymidylatsynthase ATE344835T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9720107.3A GB9720107D0 (en)	1997-09-23	1997-09-23	Compounds
GBGB9722012.3A GB9722012D0 (en)	1997-10-17	1997-10-17	Compounds
GBGB9812140.3A GB9812140D0 (en)	1998-06-06	1998-06-06	Compounds

Publications (1)

Publication Number	Publication Date
ATE344835T1 true ATE344835T1 (de)	2006-11-15

Family

ID=27269028

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98942944T ATE344835T1 (de)	1997-09-23	1998-09-17	Antisense-oligonukleotide gegen thymidylatsynthase

Country Status (9)

Country	Link
US (1)	US20050272683A1 (de)
EP (1)	EP1017800B1 (de)
JP (1)	JP2001517681A (de)
AT (1)	ATE344835T1 (de)
AU (1)	AU9090498A (de)
CA (1)	CA2301957A1 (de)
DE (1)	DE69836384T2 (de)
ES (1)	ES2280098T3 (de)
WO (1)	WO1999015648A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003086416A1 (en) *	2002-04-08	2003-10-23	Sarissa Inc.	Combinations of antisense oligonucleotides directed against thymidylate synythase mrna and uses thereof
EP1243290A3 (de) *	1998-10-19	2004-03-17	Methylgene, Inc.	Veränderung der Genexpression durch Kombinationstherapie
US6953783B1 (en)	1998-10-19	2005-10-11	Methylgene, Inc.	Modulation of gene expression by combination therapy
EP1459762B1 (de) *	2001-11-02	2008-07-02	Yoshiko Yasuda	Verwendung von emp9 zur prävention von proliferativen organerkrankungen
US20050148771A1 (en)	2004-01-05	2005-07-07	Applera Corporation.	Active esters of N-substituted piperazine acetic acids, including isotopically enriched versions thereof
CA2595573A1 (en) *	2004-01-23	2005-08-04	D. James Koropatnick	Methods of treating mesothelioma using an antisense oligonucleotide to thymidylate synthase
WO2005093090A1 (en) *	2004-03-26	2005-10-06	Sarissa Inc.	Antisense oligonucleotides and uses thereof in improving cancer treatment strategies
EP2300017A4 (de) *	2008-06-05	2012-12-12	Univ New York State Res Found	Mirnas als therapeutische targets bei krebs
SG11201507496UA (en)	2013-04-17	2015-11-27	Pfizer	N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0290144A1 (de) *	1987-05-05	1988-11-09	City of Hope	Verfahren zum Nachweis von beginnender Widerstandsfähigkeit gegen therapeutische Agenzien bei Krebskranken
US6416987B1 (en) *	1997-02-04	2002-07-09	Sloan Kettering Institute For Cancer Research	Mutants of thymidylate synthase and uses thereof
AU7364998A (en) *	1997-04-30	1998-11-24	Hybridon, Inc.	Antisense oligonucleotides specific for thymidylate synthase
US6087489A (en) *	1998-06-02	2000-07-11	Isis Pharmaceuticals Inc.	Antisense oligonucleotide modulation of human thymidylate synthase expression

1998
- 1998-09-17 AU AU90904/98A patent/AU9090498A/en not_active Abandoned
- 1998-09-17 CA CA002301957A patent/CA2301957A1/en not_active Abandoned
- 1998-09-17 JP JP2000512940A patent/JP2001517681A/ja active Pending
- 1998-09-17 WO PCT/GB1998/002820 patent/WO1999015648A1/en not_active Ceased
- 1998-09-17 DE DE69836384T patent/DE69836384T2/de not_active Expired - Lifetime
- 1998-09-17 EP EP98942944A patent/EP1017800B1/de not_active Expired - Lifetime
- 1998-09-17 ES ES98942944T patent/ES2280098T3/es not_active Expired - Lifetime
- 1998-09-17 AT AT98942944T patent/ATE344835T1/de not_active IP Right Cessation
2005
- 2005-07-01 US US11/171,435 patent/US20050272683A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1017800A1 (de)	2000-07-12
EP1017800B1 (de)	2006-11-08
WO1999015648A1 (en)	1999-04-01
JP2001517681A (ja)	2001-10-09
US20050272683A1 (en)	2005-12-08
DE69836384T2 (de)	2008-02-21
DE69836384D1 (de)	2006-12-21
ES2280098T3 (es)	2007-09-01
CA2301957A1 (en)	1999-04-01
AU9090498A (en)	1999-04-12

Legal Events

Date	Code	Title	Description
2007-05-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
EP2305251A3 (de)	2011-05-18	Pharmazeutische Zubereitungen die Clavulansäure oder Derivate enthalten zur Behandlung von sexuellen Störungen
WO2006060641A3 (en)	2006-08-17	Methods for targeted delivery of genetic material to the liver
AU2002234598A1 (en)	2002-07-16	Use of dipeptylpeptidase iv and aminopeptidase-n inhibitors in the treatment of ischaemia-induced neuro-degeneration
BR9909717A (pt)	2000-12-26	Fatores angiogênicos terapêuticos e métodos para seu uso
WO2001010468A3 (en)	2002-01-17	Drug-carrier complexes and methods of use thereof
EP2216029A3 (de)	2010-12-22	Oligonukleotide zur Behandlung von Prostatakrebs und anderen Krebserkrankungen
DE69836384D1 (de)	2006-12-21	Antisense-oligonukleotide gegen thymidylatsynthase
IL150818A0 (en)	2003-02-12	Composition for intestinal delivery
AU3295700A (en)	2000-09-28	Oligonucleotides containing an antisense sequence stabilised by a secondary structure and pharmaceutical compositions containing same
WO2002102311A3 (en)	2003-03-27	Nanoparticles for treating targeted tissues and cells
AU8243198A (en)	1999-02-10	Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors
WO2000040592A8 (en)	2000-11-09	Acid stable backbone modified end-blocked nucleic acids and therapeutic uses thereof
WO2002087509A3 (en)	2003-03-20	Colloidal metal compositions and methods
WO2001041747A3 (de)	2002-02-07	Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
AU1490801A (en)	2001-05-30	Targeted delivery of therapeutic and diagnostic moieties
WO2004013313A3 (en)	2004-10-28	Antisense nucleic acids
AU2001233957A1 (en)	2001-09-03	Proteins, genes and their use for diagnosis and treatment of bipolar affective disorder (bad) and unipolar depression
WO2003007876A3 (en)	2009-09-17	N-fatty acid-amino acid conjugates and therapeutic uses
Brand	2001	Topical and transdermal delivery of antisense oligonucleotides
WO2001024764A3 (en)	2001-08-23	Cell targeting compositions and methods of using the same
AU6258999A (en)	2000-04-03	Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
AU2001234831A1 (en)	2001-08-14	Magnetoliposome composition for targeted treatment of biological tissue and associated methods
WO2004083155A3 (en)	2005-03-31	Nucleotide lipid ester derivatives
EP1173192A4 (de)	2002-05-02	Verfahren und zusammensetzungen für eine gezielte verabreichung von medikamenten
PL1618195T3 (pl)	2008-09-30	Sposób selektywnego hamowania ludzkiego genu N-myc w nowotworach z ekspresją N-myc przez antysensowne i sensowne kwasy peptydonukleinowe